Search Results - "Pérol, D."

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J.-Y., Honoré, C., Stoeckle, E., Meeus, P., Jafari, M., Gouin, F., Anract, P., Ferron, G., Rochwerger, A., Ropars, M., Carrere, S., Marchal, F., Sirveaux, F., Di Marco, A., Le Nail, L.R., Guiramand, J., Vaz, G., Machiavello, J.-C., Marco, O., Causeret, S., Gimbergues, P., Fiorenza, F., Chaigneau, L., Guillemin, F., Guilloit, J.-M., Dujardin, F., Spano, J.-P., Ruzic, J.-C., Michot, A., Soibinet, P., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Perrin, C., Firmin, N., Bertucci, F., Le Pechoux, C., Le Loarer, F., Collard, O., Karanian-Philippe, M., Brahmi, M., Dufresne, A., Dupré, A., Ducimetière, F., Giraud, A., Pérol, D., Toulmonde, M., Ray-Coquard, I., Italiano, A., Le Cesne, A., Penel, N., Bonvalot, S.

“…NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of…”
Get full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer by Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp

“…When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a…”
Get full text

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial by Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., Heudel, P.-E., Bonneville-Levard, A., Fléchon, A., Sarabi, M., Guibert, P., Bachelot, T., Pérol, M., You, B., Bonnin, N., Collard, O., Leyronnas, C., Attignon, V., Baudet, C., Sohier, E., Villemin, J.-P., Viari, A., Boyault, S., Lantuejoul, S., Paindavoine, S., Treillleux, I., Rodriguez, C., Agrapart, V., Corset, V., Garin, G., Chabaud, S., Pérol, D., Blay, J.-Y.

“…Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological subtypes. We aim to explore…”
Get full text

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort by Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., Delaloge, S.

“…Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit…”
Get full text

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study by Delaloge, S., Pérol, D., Courtinard, C., Brain, E., Asselain, B., Bachelot, T., Debled, M., Dieras, V., Campone, M., Levy, C., Jacot, W., Lorgis, V., Veyret, C., Dalenc, F., Ferrero, J.M., Uwer, L., Kerbrat, P., Goncalves, A., Mouret-Reynier, M.A., Petit, T., Jouannaud, C., Vanlemmens, L., Chenuc, G., Guesmia, T., Robain, M., Cailliot, C.

“…Bevacizumab combined with paclitaxel as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC) has led to mixed results in…”
Get full text

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients by Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P.E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A.C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N'Kodia, A., Gilles-Afchain, L., Morre, M., Pérol, D., Blay, J.Y., Caux, C.

“…Lymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107…”
Get full text

Surgery in reference centers improves survival of sarcoma patients: a nationwide study by Blay, J -Y, Honoré, C, Stoeckle, E, Meeus, P, Jafari, M, Gouin, F, Anract, P, Ferron, G, Rochwerger, A, Ropars, M, Carrere, S, Marchal, F, Sirveaux, F, Di Marco, A, Le Nail, L R, Guiramand, J, Vaz, G, Machiavello, J -C, Marco, O, Causeret, S, Gimbergues, P, Fiorenza, F, Chaigneau, L, Guillemin, F, Guilloit, J -M, Dujardin, F, Spano, J -P, Ruzic, J -C, Michot, A, Soibinet, P, Bompas, E, Chevreau, C, Duffaud, F, Rios, M, Perrin, C, Firmin, N, Bertucci, F, Le Pechoux, C, Le Loarer, F, Collard, O, Karanian-Philippe, M, Brahmi, M, Dufresne, A, Dupré, A, Ducimetière, F, Giraud, A, Pérol, D, Toulmonde, M, Ray-Coquard, I, Italiano, A, Le Cesne, A, Penel, N, Bonvalot, S

Get full text

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie by NEGRIER, S, ESCUDIER, B, GOMEZ, F, DOUILLARD, J.-Y, RAVAUD, A, CHEVREAU, C, BUCLON, M, PEROL, D, LASSET, C

“…Interleukin-2 (IL-2) or/and interferon (IFN) are routinely used for treating patients with metastatic renal cell cancer. However, results have been…”
Get full text

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients by Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P.E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A.C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N’Kodia, A., Gilles-Afchain, L., Morre, M., Pérol, D., Blay, J.Y., Caux, C.

Get full text

Actionable molecular alterations in advanced gynecologic malignancies: updated results from the ProfiLER program in France by Le Saux, O., Ray-Coquard, I., Corset, V., Sohier, E., Baudet, C., Pissaloux, D., Wang, Q., Chabaud, S., Varnier, R., Heudel, P., Derbel, O., You, B., Trédan, O., Cassier, P., Bonnin, N., Biron, P., Freyer, G., Trillet-Lenoir, V., Bachelot, T., Pérol, D., Blay, J-Y

Get full text

Intra-operative ablation of colorectal liver metastases (CLM) with high intensity focused ultrasound (HIFU): Preliminary results of a prospective ablate-and-resect study by Dupré, A, Melodelima, D, Chen, Y, Pérol, D, Kocot, A, Vincenot, J, Rivoire, M

Get full text

A Cost-Analysis of Complex Radiotherapy in Patients with Head and Neck Cancer Results from the Art-Orl Study by Perrier, L, Morelle, M, Pommier, P, Boisselier, P, Lartigau, E, Gallocher, O, Alfonsi, M, Bardet, E, Rives, M, Calugaru, V, Chajon, E, Noel, G, Mecellem, H, Pérol, D, Dussart, S, Giraud, P

Get full text

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial by Patrikidou, A., Chabaud, S., Ray-Coquard, I., Bui, B.N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Domont, J., Pérol, D., Blay, J.Y., Le Cesne, A.

“…We previously demonstrated that interruption of imatinib mesylate (IM) in responding patients (pts) with advanced gastrointestinal stromal tumours (GISTs)…”
Get full text

Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study by Bourmaud, A, Anota, A, Moncharmont, C, Tinquaut, F, Oriol, M, Trillet-Lenoir, V, Bajard, A, Parnalland, S, Rotonda, C, Bonnetain, F, Pérol, D, Chauvin, F

“…Background: To assess the efficacy of a patient educational program built according to guidelines that aims at reducing cancer-related fatigue (CRF). Methods:…”
Get full text

Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer by Heudel, P., Chabaud, S., Perol, D., Ray-Coquard, I., Blay, J.-Y.

Get full text

Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor ‘Checkpoint inhibition: protecting against or predisposing for second primary tumors?’ by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs by Heudel, P., Chabaud, S., Perol, D., Ray-Coquard, I., Blay, J.-Y.

Get full text

Reply to ‘The potential and perils of observational studies’ by M. Buyse et al by Delaloge, S., Pérol, D., Robain, M., Cailliot, C.

Get full text

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up by Penel, N., Le Cesne, A., Bui, B.N., Perol, D., Brain, E.G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., Jimenez, M., Duffaud, F., Piperno-Neumann, S., Mignot, L., Blay, J.-Y.

“…Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT). Forty…”
Get full text

PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA by Perrier, L, Lefranc, A, Quittet, P, Moreau, P, Siani, C, Ghesquières, H, Jardin, F, Favier, B, Ifrah, N, Lissandre, S, Pérol, D, Sebban, C

Get full text

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial by Fléchon, A., Pouessel, D., Ferlay, C., Perol, D., Beuzeboc, P., Gravis, G., Joly, F., Oudard, S., Deplanque, G., Zanetta, S., Fargeot, P., Priou, F., Droz, J.P., Culine, S.

“…In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine…”
Get full text